NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri

Annals of Neurology

Volumn 70, Issue 3, 2011, Pages 445-453

  Glas, Martin ^a   Bähr, Oliver ^b,c   Felsberg, Jörg ^d   Rasch, Katja ^a   Wiewrodt, Dorothee ^e   Schabet, Martin ^f   Simon, Matthias ^a   Urbach, Horst ^a   Steinbach, Joachim P ^b,c   Rieger, Johannes ^b,c   Fimmers, Rolf ^a   Bamberg, Michael ^c   Nägele, Thomas ^c   Reifenberger, Guido ^d   Weller, Michael ^c,g   Herrlinger, Ulrich ^a,c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Ludwigsburg Clinic   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLGUANINE DNA METHYLTRANSFERASE; PROCARBAZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOSIS; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ENDPOINT DETERMINATION; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS, NEUROEPITHELIAL; PROCARBAZINE; PROGNOSIS; PROSPECTIVE STUDIES; SAMPLE SIZE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 80052581228     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22478     Document Type: Article

References (22)

1. Louis D, Ohgaki H, Wiestler O, et al, eds. WHO classification of tumours of the central nervous system. Lyon, France: IARC Press, 2007.
2. Taillibert S, Chodkiewicz C, Laigle-Donadey F, et al. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 2006; 76: 201-205. (Pubitemid 43125749)
3. Perkins GH, Schomer DF, Fuller GN, et al. Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 1137-1146. (Pubitemid 36794048)
4. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004; 63: 270-275. (Pubitemid 38971125)
5. Kaloshi G, Everhard S, Laigle-Donadey F, et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 2008; 70: 590-595. (Pubitemid 351294636)
6. Levin N, Gomori JM, Siegal T,. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology 2004; 63: 354-356. (Pubitemid 38971142)
7. Herrlinger U, Felsberg J, Küker W, et al. Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 2002; 52: 390-399.
8. Glas M, Rasch K, Wiewrodt D, et al. Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology 2008; 75: 182-185.
9. Simon R,. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
10. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280. (Pubitemid 20195640)
12. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
13. Horst E, Micke O, Romppainen ML, et al. Radiation therapy approach in gliomatosis cerebri-case reports and literature review. Acta Oncol 2000; 39: 747-751.
14. Elshaikh MA, Stevens GH, Peereboom DM, et al. Gliomatosis cerebri: treatment results with radiotherapy alone. Cancer 2002; 95: 2027-2031. (Pubitemid 35222184)
15. Soffietti R, Rudà R, Laguzzi E, et al. Treatment of gliomatosis cerebri with temozolomide: a retrospective study of the AINO (Italian Association for Neuro-Oncology) [abstract]. J Clin Oncol 2007; 25 (18 suppl). Abstract 2033.
16. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
17. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
18. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-1604.
19. Armstrong GT, Phillips PC, Rorke-Adams LB, et al. Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia. Cancer 2006; 107: 1597-1606. (Pubitemid 44546921)
20. Ware ML, Hirose Y, Scheithauer BW, et al. Genetic aberrations in gliomatosis cerebri. Neurosurgery 2007; 60: 150-158. (Pubitemid 46102961)
21. Seiz M, Tuettenberg J, Meyer J, et al. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 2010; 120: 261-267.
22. D'Urso OF, D'Urso PI, Marsigliante S, et al. Correlative analysis of gene expression profile and prognosis in patients with gliomatosis cerebri. Cancer 2009; 115: 3749-3757.